3D Holographic Guidance, Navigation, and Control for Endovascular Aortic Repair

NCT06008613 | Completed Results FDA Device

• 2 other identifiers: 23-7535R44HL139290-03
• Study Type: interventional
• Target: 2
• Locations: 1 country
• Sites: 1

Brief Summary

This is an Early Feasibility Study to evaluate the usability, safety and functionality of 3D holographic guidance, navigation, and control (3D-GNC) as an adjunct to and confirmed by fluoroscopic imaging to be used with Cook Zenith Flex AAA Endovascular Graft®.

Conditions

Abdominal Aortic Aneurysm

Keywords

AAA; EVAR

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Successful Implantation of Cook Zenith AAA Endovascular Graft Using the 3D-GN&C Device

  Number of Patients with Correct positioning of the endovascular stent graft using the 3D-GN\&C device confirmed by fluoroscopic imaging

  By the end of the procedure, average of 2 hours

Secondary Outcomes (1)

• Delivery System Placement in the Intended Location

  At the time of the procedure

Other Outcomes (1)

• Incidence of Adverse Event (AE)/Serious Adverse Event (SAE) Related to 3D-GN&C Device

  Through study completion, an average of 30 days

Study Arms (1)

Intervention

EXPERIMENTAL

Electromagnetic guidance and tracking as an adjunct to and confirmed by fluoroscopic imaging to be used with Cook Zenith Flex AAA Endovascular Graft.

Device: 3D Holographic Guidance, Navigation, and Control (3D GN&C)

Interventions

3D Holographic Guidance, Navigation, and Control (3D GN&C) DEVICE

Using electromagnetic (EM) guidance and tracking to precisely place a Cook Zenith Flex AAA bifurcated stent graft during EVAR. EM guidance and tracking is enabled using a system consisting of: 1. experimental 3D guidance, navigation, and control (3D-GNC) software developed by Centerline Biomedical, Inc., integrated with the company's FDA-cleared Intra-Operative Positioning System (IOPS), 2. FDA-cleared compatible sensorized guidewires added to the Cook Zenith Flex delivery system, and 3. 3D visualization on the IOPS mobile cart monitor and 3D holographic visualization overlaid on the patient during the procedure using a head mounted display (HMD), the Microsoft HoloLens 2.

Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient meets the instructions for use (IFU) for the 24-28 mm body Cook Zenith Flex AAA bifurcated stent graft.
• Adequate iliac/femoral access compatible with the required introduction system
• Non aneurysmal infrarenal aortic segment (neck) proximal to the aneurysm:
• i. With a length of at least 15mm ii. With a diameter measured outer wall to outer wall of no greater than 26mm and no less than 20mm iii. With an angle less than 60 degrees relative to the long access of the aneurysm and iv. With an angle less than 45 degrees relative to the axis of the suprarenal aorta c. Iliac artery distal fixation site greater than 10mm in length and 7.5-20mm in diameter (measured outerwall to outerwall).
• Male/female, aged ≥ 18
• Patient fulfilling criteria for needing endovascular repair of abdominal aortic aneurysm according to routine clinical practice criteria of the participating center
• Women of childbearing potential must be non-pregnant, non-lactating, and not planning to become pregnant during the course of the trial; and have a negative urine or serum pregnancy test within 7 days prior to index procedure
• Provide written informed consent as applicable and defined by site country regulation
• Stated willingness to comply with all study procedures and availability for the duration of the study

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in this study:
• Contraindications for Cook Zenith Flex Aortic endograft:
• Patients with known sensitivities or allergies to stainless steel, polyester, solder (tin, silver), polypropylene, or gold
• Patients with a systemic infection who may be at increased risk of endovascular graft infection
• Presence of electronic implants, e.g., cardiac pacemaker, automatic implantable cardioverter/defibrillator (AICD) or nerve stimulator
• Presence of metallic implants above the knee, e.g., artificial hip
• Patients not willing or able to give informed consent
• Pregnant women
• Patients' inability to have a contrasted CT scan
• Current or planned participation in any other investigational drug or medical device clinical study that has not completed primary endpoint(s) evaluation;
• Other medical, social, or psychological issues that in the opinion of the investigator preclude the subjects from receiving this treatment, and the procedures and evaluations pre- and posttreatment
• Anatomy outside of the IFU for a 24-28 mm Cook Zenith Flex AAA bifurcated stent graft

Sponsors & Collaborators

• The Cleveland Clinic: lead
• National Heart, Lung, and Blood Institute (NHLBI): collaborator

Study Sites (1)

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

MeSH Terms

Conditions

Aortic Aneurysm, Abdominal

Condition Hierarchy (Ancestors)

Aortic Aneurysm; Aneurysm; Vascular Diseases; Cardiovascular Diseases; Aortic Diseases

Results Point of Contact

• Title: Francis Caputo, MD
• Organization: Cleveland Clinic

CAPUTOF@ccf.org

216-445-9580

Study Officials

• Francis Caputo, MD

  The Cleveland Clinic

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 9, 2023
• First Posted: August 23, 2023
• Study Start: October 18, 2023
• Primary Completion: June 19, 2025
• Study Completion: June 19, 2025
• Last Updated: April 24, 2026
• Results First Posted: April 24, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)